150 related articles for article (PubMed ID: 23790244)
1. What do we know about the safety of corticosteroids in rheumatoid arthritis?
Ethgen O; de Lemos Esteves F; Bruyere O; Reginster JY
Curr Med Res Opin; 2013 Sep; 29(9):1147-60. PubMed ID: 23790244
[TBL] [Abstract][Full Text] [Related]
2. Are glucocorticoids harmful to bone in early rheumatoid arthritis?
Lems WF
Ann N Y Acad Sci; 2014 May; 1318():50-4. PubMed ID: 24739059
[TBL] [Abstract][Full Text] [Related]
3. Glucocorticoid safety for treating rheumatoid arthritis.
Rasch LA; Bultink IE; van Tuyl LH; Lems WF
Expert Opin Drug Saf; 2015 Jun; 14(6):839-44. PubMed ID: 25802019
[TBL] [Abstract][Full Text] [Related]
4. Low-dose glucocorticoid therapy in rheumatoid arthritis: an obligatory therapy.
Bijlsma JW; van der Goes MC; Hoes JN; Jacobs JW; Buttgereit F; Kirwan J
Ann N Y Acad Sci; 2010 Apr; 1193():123-6. PubMed ID: 20398017
[TBL] [Abstract][Full Text] [Related]
5. Rheumatoid arthritis, treatment with corticosteroids and risk of malignant lymphomas: results from a case-control study.
Hellgren K; Iliadou A; Rosenquist R; Feltelius N; Backlin C; Enblad G; Askling J; Baecklund E
Ann Rheum Dis; 2010 Apr; 69(4):654-9. PubMed ID: 19439429
[TBL] [Abstract][Full Text] [Related]
6. Canadian Rheumatology Association recommendations for the pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs: part II safety.
Bombardier C; Hazlewood GS; Akhavan P; Schieir O; Dooley A; Haraoui B; Khraishi M; Leclercq SA; Légaré J; Mosher DP; Pencharz J; Pope JE; Thomson J; Thorne C; Zummer M; Gardam MA; Askling J; Bykerk V;
J Rheumatol; 2012 Aug; 39(8):1583-602. PubMed ID: 22707613
[TBL] [Abstract][Full Text] [Related]
7. Pharmacology of glucocorticoids in rheumatoid arthritis.
Spies CM; Bijlsma JW; Burmester GR; Buttgereit F
Curr Opin Pharmacol; 2010 Jun; 10(3):302-7. PubMed ID: 20202903
[TBL] [Abstract][Full Text] [Related]
8. Glucocorticoids in rheumatoid arthritis: the silent companion in the therapeutic strategy.
Berardicurti O; Ruscitti P; Pavlych V; Conforti A; Giacomelli R; Cipriani P
Expert Rev Clin Pharmacol; 2020 Jun; 13(6):593-604. PubMed ID: 32434398
[TBL] [Abstract][Full Text] [Related]
9. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK
J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
[TBL] [Abstract][Full Text] [Related]
10. Safety profile of abatacept in rheumatoid arthritis: a review.
Khraishi M; Russell A; Olszynski WP
Clin Ther; 2010 Oct; 32(11):1855-70. PubMed ID: 21095481
[TBL] [Abstract][Full Text] [Related]
11. To treat or not to treat rheumatoid arthritis with glucocorticoids? A reheated debate.
Cutolo M; Shoenfeld Y; Bogdanos DP; Gotelli E; Salvato M; Gunkl-Tóth L; Nagy G
Autoimmun Rev; 2024 Jan; 23(1):103437. PubMed ID: 37652398
[TBL] [Abstract][Full Text] [Related]
12. [Glucocorticoids].
Tanaka H; Hosono O; Kobayashi H; Yoshikawa N; Matsumiya R
Nihon Rinsho; 2013 Jul; 71(7):1261-5. PubMed ID: 23961677
[TBL] [Abstract][Full Text] [Related]
13. Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use.
Proudman SM; Keen HI; Stamp LK; Lee AT; Goldblatt F; Ayres OC; Rischmueller M; James MJ; Hill CL; Caughey GE; Cleland LG
Semin Arthritis Rheum; 2007 Oct; 37(2):99-111. PubMed ID: 17391739
[TBL] [Abstract][Full Text] [Related]
14. Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis.
Schneeweiss S; Setoguchi S; Weinblatt ME; Katz JN; Avorn J; Sax PE; Levin R; Solomon DH
Arthritis Rheum; 2007 Jun; 56(6):1754-64. PubMed ID: 17530704
[TBL] [Abstract][Full Text] [Related]
15. Serious infections in a population-based cohort of 86,039 seniors with rheumatoid arthritis.
Widdifield J; Bernatsky S; Paterson JM; Gunraj N; Thorne JC; Pope J; Cividino A; Bombardier C
Arthritis Care Res (Hoboken); 2013 Mar; 65(3):353-61. PubMed ID: 22833532
[TBL] [Abstract][Full Text] [Related]
16. [Glucocorticoids in rheumatoid arthritis: almost always or hardly ever?].
Blanco-Morales EA; Bravo-Ferrer Acosta JM; Rubio Romero E; Gil González E; Gantes Pedraza MÁ
Reumatol Clin; 2011; 7(6):407-11. PubMed ID: 22078702
[TBL] [Abstract][Full Text] [Related]
17. Short-term and long-term safety of glucocorticoids in rheumatoid arthritis.
Saag KG
Bull NYU Hosp Jt Dis; 2012; 70 Suppl 1():21-5. PubMed ID: 23259654
[TBL] [Abstract][Full Text] [Related]
18. Safety of extended treatment with anakinra in patients with rheumatoid arthritis.
Fleischmann RM; Tesser J; Schiff MH; Schechtman J; Burmester GR; Bennett R; Modafferi D; Zhou L; Bell D; Appleton B
Ann Rheum Dis; 2006 Aug; 65(8):1006-12. PubMed ID: 16396977
[TBL] [Abstract][Full Text] [Related]
19. TNF antagonist safety in rheumatoid arthritis: updated evidence from observational registries.
Nasir A; Greenberg JD
Bull NYU Hosp Jt Dis; 2007; 65(3):178-81. PubMed ID: 17922666
[TBL] [Abstract][Full Text] [Related]
20. Efficacy, duration of use and safety of glucocorticoids: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis.
Bergstra SA; Sepriano A; Kerschbaumer A; van der Heijde D; Caporali R; Edwards CJ; Verschueren P; de Souza S; Pope JE; Takeuchi T; Hyrich KL; Winthrop KL; Aletaha D; Stamm TA; Schoones JW; Smolen JS; Landewé RBM
Ann Rheum Dis; 2023 Jan; 82(1):81-94. PubMed ID: 36410794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
